Treating rheumatoid arthritis to target: recommendations of an international task force
Open accessThe DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.
Abstract
Background Aiming at therapeutic targets has reduced the risk of organ failure in many diseases such as diabetes or hypertension. Such targets have not been defined for rheumatoid arthritis (RA). Objective To develop recommendations for achieving optimal therapeutic outcomes in RA. Methods A task force of rheumatologists and a patient developed a set of recommendations on the basis of evidence derived from a systematic literature review and expert opinion; these were subsequently discussed, amended and voted upon by >60 experts from various regions of the world in a Delphi-like procedure. Levels of evidence, strength of recommendations and levels of agreement were derived. Results The treat-to-target activity resulted in 10 recommendations. The treatment aim was defined as remission with low disease activity being an alternative goal in patients with long-standing disease. Regular follow-up (every 1–3 months during active disease) with appropriate therapeutic adaptation to reach the desired state within 3 to a maximum of 6 months was recommended. Follow-up examinations ought to employ composite measures of disease activity which include joint counts. Additional items provide further details for particular aspects of the disease. Levels of agreement were very high for many of these recommendations (≥9/10). Conclusion The 10 recommendations are supposed to inform patients, rheumatologists and other stakeholders about strategies to reach optimal outcomes of RA based on evidence and expert opinion.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000344393.60303.0a · Cited by 3,641
Felson, D. T., Anderson, J. J., Boers, M., Bombardier, C., Chernoff, M., Fried, B., Furst, D., Goldsmith, C., Kieszak, S., Lightfoot, R., et al. (1993) · Arthritis & Rheumatism · doi:10.1002/art.1780360601 · Cited by 1,640
(2003) · Quality and Safety in Health Care · doi:10.1136/qhc.12.1.18 · Cited by 1,446
Grigor, C., Capell, H., Stirling, A., McMahon, A. D., Lock, P., Vallance, R., Porter, D., & Kincaid, W. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16676-2 · Cited by 1,435
Clinical guidelines: Developing guidelines
Shekelle, P. G., Woolf, S. H., Eccles, M., & Grimshaw, J. (1999) · BMJ · doi:10.1136/bmj.318.7183.593 · Cited by 1,222
Saag, K. G., Teng, G. G., Patkar, N. M., Anuntiyo, J., Finney, C., Curtis, J. R., Paulus, H. E., Mudano, A., Pisu, M., Elkins‐Melton, M., et al. (2008) · Arthritis Care & Research · doi:10.1002/art.23721 · Cited by 1,157
Emery, P., Keystone, E., Tony, H. P., Cantagrel, A., van Vollenhoven, R., Sanchez, A., Alecock, E., Lee, J., & Kremer, J. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.092932 · Cited by 1,104
Self-citationA simplified disease activity index for rheumatoid arthritis for use in clinical practice
Smolen, J. S., Breedveld, F. C., Schiff, M. H., Kalden, J. R., Emery, P., Eberl, G., van Riel, P. L., & Tugwell, P. (2003) · Rheumatology · doi:10.1093/rheumatology/keg072 · Cited by 1,071
Self-citation
Cited by
Smolen, J. S., Landewé, R., Bijlsma, J., Burmester, G., Chatzidionysiou, K., Dougados, M., Nam, J., Ramiro, S., Voshaar, M., van Vollenhoven, R., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210715 · Cited by 2,057
Self-citationSmolen, J. S., Landewé, R., Breedveld, F. C., Buch, M., Burmester, G., Dougados, M., Emery, P., Gaujoux-Viala, C., Gossec, L., Nam, J., et al. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204573 · Cited by 1,763
Self-citationSmolen, J. S., Breedveld, F. C., Burmester, G. R., Bykerk, V., Dougados, M., Emery, P., Kvien, T. K., Navarro-Compán, M. V., Oliver, S., Schoels, M., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-207524 · Cited by 1,465
Self-citationFelson, D. T., Smolen, J. S., Wells, G., Zhang, B., van Tuyl, L. H. D., Funovits, J., Aletaha, D., Allaart, C. F., Bathon, J., Bombardieri, S., et al. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30129 · Cited by 1,022
Self-citationThe etiology of rheumatoid arthritis
Scherer, H. U., Häupl, T., & Burmester, G. R. (2020) · Journal of Autoimmunity · doi:10.1016/j.jaut.2019.102400 · Cited by 881
Self-citationDi Matteo, A., Bathon, J. M., & Emery, P. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01525-8 · Cited by 849
Self-citationFelson, D. T., Smolen, J. S., Wells, G., Zhang, B., van Tuyl, L. H. D., Funovits, J., Aletaha, D., Allaart, C. F., Bathon, J., Bombardieri, S., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2011.149765 · Cited by 777
Self-citationAnderson, J., Caplan, L., Yazdany, J., Robbins, M. L., Neogi, T., Michaud, K., Saag, K. G., O'dell, J. R., & Kazi, S. (2012) · Arthritis Care & Research · doi:10.1002/acr.21649 · Cited by 748
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force
van Vollenhoven, R. F., Mosca, M., Bertsias, G., Isenberg, D., Kuhn, A., Lerstrøm, K., Aringer, M., Bootsma, H., Boumpas, D., Bruce, I. N., et al. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-205139 · Cited by 740
Self-citationGlobal epidemiology of rheumatoid arthritis
Finckh, A., Gilbert, B., Hodkinson, B., Bae, S.-C., Thomas, R., Deane, K. D., Alpizar-Rodriguez, D., & Lauper, K. (2022) · Nature Reviews Rheumatology · doi:10.1038/s41584-022-00827-y · Cited by 736
Burmester, G. R., Blanco, R., Charles-Schoeman, C., Wollenhaupt, J., Zerbini, C., Benda, B., Gruben, D., Wallenstein, G., Krishnaswami, S., Zwillich, S. H., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61424-x · Cited by 714
Self-citationTofacitinib versus methotrexate in rheumatoid arthritis
Lee, E. B., Fleischmann, R., Hall, S., Wilkinson, B., Bradley, J. D., Gruben, D., Koncz, T., Krishnaswami, S., Wallenstein, G. V., Zang, C., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1310476 · Cited by 711
Smolen, J. S., Schöls, M., Braun, J., Dougados, M., FitzGerald, O., Gladman, D. D., Kavanaugh, A., Landewé, R., Mease, P., Sieper, J., et al. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-211734 · Cited by 682
Self-citationRheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges
Smolen, J. S., & Aletaha, D. (2015) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.8 · Cited by 474
Self-citationBrain health: time matters in multiple sclerosis
Giovannoni, G., Butzkueven, H., Dhib-Jalbut, S., Hobart, J., Kobelt, G., Pepper, G., Sormani, M. P., Thalheim, C., Traboulsee, A., & Vollmer, T. (2016) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2016.07.003 · Cited by 458
Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis
Buch, M. H., Smolen, J. S., Betteridge, N., Breedveld, F. C., Burmester, G., Dörner, T., Ferraccioli, G., Gottenberg, J.-E., Isaacs, J., Kvien, T. K., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.144998 · Cited by 453
Self-citationStoffer, M. A., Schoels, M. M., Smolen, J. S., Aletaha, D., Breedveld, F. C., Burmester, G., Bykerk, V., Dougados, M., Emery, P., Haraoui, B., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-207526 · Cited by 451
Self-citationSmolen, J. S., Braun, J., Dougados, M., Emery, P., FitzGerald, O., Helliwell, P., Kavanaugh, A., Kvien, T. K., Landewé, R., Luger, T., et al. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-203419 · Cited by 447
Self-citationFleischmann, R., Pangan, A. L., Song, I., Mysler, E., Bessette, L., Peterfy, C., Durez, P., Ostor, A. J., Li, Y., Zhou, Y., et al. (2019) · Arthritis & Rheumatology · doi:10.1002/art.41032 · Cited by 444
Smolen, J. S., Landewé, R., Breedveld, F. C., Dougados, M., Emery, P., Gaujoux-Viala, C., Gorter, S., Knevel, R., Nam, J., Schoels, M., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.126532 · Cited by 409
Self-citationSmolen, J. S., Nash, P., Durez, P., Hall, S., Ilivanova, E., Irazoque-Palazuelos, F., Miranda, P., Park, M.-C., Pavelka, K., Pedersen, R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61811-x · Cited by 357
Self-citationMease, P. J. (2011) · Arthritis Care & Research · doi:10.1002/acr.20577 · Cited by 342
Immune-mediated inflammatory disease therapeutics: past, present and future
McInnes, I. B., & Gravallese, E. M. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00603-1 · Cited by 337
Self-citationBYKERK, V. P., AKHAVAN, P., HAZLEWOOD, G. S., SCHIEIR, O., DOOLEY, A., HARAOUI, B., KHRAISHI, M., LECLERCQ, S. A., LÉGARÉ, J., MOSHER, D. P., et al. (2012) · The Journal of Rheumatology · doi:10.3899/jrheum.110207 · Cited by 335
Self-citationDejaco, C., Singh, Y. P., Perel, P., Hutchings, A., Camellino, D., Mackie, S., Abril, A., Bachta, A., Balint, P., Barraclough, K., et al. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-207492 · Cited by 334
Koźmiński, P., Halik, P. K., Chesori, R., & Gniazdowska, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103483 · Cited by 326
A 5-Year Follow-up of Rituximab Treatment in Patients With Neuromyelitis Optica Spectrum Disorder
Kim, S.-H., Huh, S.-Y., Lee, S. J., Joung, A., & Kim, H. J. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.3071 · Cited by 324
Bakker, M. F., Jacobs, J. W. G., Welsing, P. M. J., Verstappen, S. M. M., Tekstra, J., Ton, E., Geurts, M. A. W., van der Werf, J. H., van Albada-Kuipers, G. A., Jahangier-de Veen, Z. N., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-5-201203060-00004 · Cited by 322
Self-citationDejaco, C., Singh, Y. P., Perel, P., Hutchings, A., Camellino, D., Mackie, S., Abril, A., Bachta, A., Balint, P., Barraclough, K., et al. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39333 · Cited by 312
State-of-the-art: rheumatoid arthritis
McInnes, I. B., & O'Dell, J. R. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.134684 · Cited by 303
Self-citationBryant, R. V., Winer, S., SPL, T., & Riddell, R. H. (2014) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2014.08.011 · Cited by 300
Management Strategies to Improve Outcomes of Patients With Inflammatory Bowel Diseases
Colombel, J.-F., Narula, N., & Peyrin-Biroulet, L. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.09.046 · Cited by 299
Tanaka, Y., Suzuki, M., Nakamura, H., Toyoizumi, S., Zwillich, S. H., & Tofacitinib Study Investigators (2011) · Arthritis Care & Research · doi:10.1002/acr.20494 · Cited by 297
Listing, J., Kekow, J., Manger, B., Burmester, G.-R., Pattloch, D., Zink, A., & Strangfeld, A. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204021 · Cited by 295
Self-citationDougados, M., Kissel, K., Sheeran, T., Tak, P. P., Conaghan, P. G., Mola, E. M., Schett, G., Amital, H., Navarro-Sarabia, F., Hou, A., et al. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-201282 · Cited by 287
Self-citationStudenic, P., Radner, H., Smolen, J. S., & Aletaha, D. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34543 · Cited by 281
Self-citationSmolen, J. S., Emery, P., Fleischmann, R., van Vollenhoven, R. F., Pavelka, K., Durez, P., Guérette, B., Kupper, H., Redden, L., Arora, V., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61751-1 · Cited by 277
Self-citationInterleukin 6 and Rheumatoid Arthritis
Yoshida, Y., & Tanaka, T. (2014) · BioMed Research International · doi:10.1155/2014/698313 · Cited by 207
“The arrival of biological agents (biologics, biological DMARD) such as TNF inhibitors, abatacept, an inhibitor of T-cell costimulation, and rituximab, an agent leading to B-cell depletion induced a paradigm shift in the treatment of RA and Treat-to-Target (T2T) treatment proved to be successful for disease remission a…”
BackgroundHaschka, J., Englbrecht, M., Hueber, A. J., Manger, B., Kleyer, A., Reiser, M., Finzel, S., Tony, H.-P., Kleinert, S., Feuchtenberger, M., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-206439 · Cited by 201
Norton, S., Koduri, G., Nikiphorou, E., Dixey, J., Williams, P., & Young, A. (2013) · Rheumatology · doi:10.1093/rheumatology/kes262 · Cited by 193
Biologic therapies and bone loss in rheumatoid arthritis
on behalf of the IOF Chronic Inflammation and Bone Structure (CIBS) Working Group, Zerbini, C. A. F., Clark, P., Mendez-Sanchez, L., Pereira, R. M. R., Messina, O. D., Uña, C. R., Adachi, J. D., Lems, W. F., Cooper, C., et al. (2017) · Osteoporosis International · doi:10.1007/s00198-016-3769-2 · Cited by 191
Klarenbeek, N. B., Güler-Yüksel, M., van der Kooij, S. M., Han, K. H., Ronday, H. K., Kerstens, P. J. S. M., Seys, P. E. H., Huizinga, T. W. J., Dijkmans, B. A. C., & Allaart, C. F. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.141234 · Cited by 180
“together with the introduction of dynamic tightly controlled treatment aimed at a predefined goal,”
BackgroundPiga, M., Cangemi, I., Mathieu, A., & Cauli, A. (2017) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2017.03.014 · Cited by 178
Orr, C. K., Najm, A., Young, F., McGarry, T., Biniecka, M., Fearon, U., & Veale, D. J. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00185 · Cited by 170
Diagnosis and classification of rheumatoid arthritis
Kourilovitch, M., Galarza-Maldonado, C., & Ortiz-Prado, E. (2014) · Journal of Autoimmunity · doi:10.1016/j.jaut.2014.01.027 · Cited by 168
““Windows of opportunity” [52] and “Treat to Target” [53] are current management strategies in the treatment of RA.”
BackgroundDougados, M., Soubrier, M., Perrodeau, E., Gossec, L., Fayet, F., Gilson, M., Cerato, M.-H., Pouplin, S., Flipo, R.-M., Chabrefy, L., et al. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204733 · Cited by 163
Self-citationProudman, S. M., James, M. J., Spargo, L. D., Metcalf, R. G., Sullivan, T. R., Rischmueller, M., Flabouris, K., Wechalekar, M. D., Lee, A. T., & Cleland, L. G. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204145 · Cited by 163
Koike, T., Harigai, M., Ishiguro, N., Inokuma, S., Takei, S., Takeuchi, T., Yamanaka, H., Haruna, S., Ushida, N., Kawana, K., et al. (2014) · Modern Rheumatology · doi:10.3109/14397595.2013.843760 · Cited by 160
Pasma, A., van't Spijker, A., Hazes, J. M. W., Busschbach, J. J. V., & Luime, J. J. (2013) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2012.12.001 · Cited by 155
Kaneko, Y., Atsumi, T., Tanaka, Y., Inoo, M., Kobayashi-Haraoka, H., Amano, K., Miyata, M., Murakawa, Y., Yasuoka, H., Hirata, S., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-208426 · Cited by 96
Noordali, F., Cumming, J., & Thompson, J. L. (2017) · Journal of Health Psychology · doi:10.1177/1359105315620293 · Cited by 84
Taylor‐Gjevre, R., Nair, B., Bath, B., Okpalauwaekwe, U., Sharma, M., Penz, E., Trask, C., & Stewart, S. A. (2018) · Musculoskeletal Care · doi:10.1002/msc.1215 · Cited by 67
Ziade, N., Arayssi, T., Elzorkany, B., Daher, A., Karam, G. A., Jbara, M. A., Aiko, A., Alam, E., Emadi, S. A., Mashaleh, M. A., et al. (2021) · Mediterranean Journal of Rheumatology · doi:10.31138/mjr.32.1.66 · Cited by 12
Metadata
- Authors
- Smolen, J. S., Aletaha, D., Bijlsma, J. W. J., Breedveld, F. C., Boumpas, D., Burmester, G., Combe, B., Cutolo, M., de Wit, M., Dougados, M., Emery, P., Gibofsky, A., Gomez-Reino, J. J., Haraoui, B., Kalden, J., Keystone, E. C., Kvien, T. K., McInnes, I., Martin-Mola, E., Montecucco, C., Schoels, M., & van der Heijde, D.
- Venue
- Annals of the Rheumatic Diseases
- Publisher
- Elsevier BV
- Published
- 2010-05
- Volume
- 69
- Issue
- 4
- Pages
- 631-637
- ISSN
- 0003-4967 (ISSN-L)
- OpenAlex
- W2155109530
- Cited by
- 2,100
- References
- 81
- FWCI
- 112.22
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.